Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SHP640 for adenoviral conjunctivitis
MOH_2017-10-10_000755Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexamethasone + povidone-iodine, povidone-iodine and dexamethasone in adenoviral conjunctivitis (3 arms), sponsored by Takeda. Primary endpoint: Clinical resolution at Visit 3 (Day 6). Planned start Aug 2017; status: not yet recruiting.
02
Drugs
dexamethasone + povidone-iodinepovidone-iodinedexamethasone
03
Conditions
adenoviral conjunctivitis
Beyond the preview
Go deeper on MOH_2017-10-10_000755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-10_000755.